Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens

Clinical Cancer Research

Volumn 15, Issue 15, 2009, Pages 4867-4874

  Cruz Munoz, William ^a   Man, Shan ^a   Kerbel, Robert S ^a  

^a SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACARBAZINE; MONOCLONAL ANTIBODY DC101; VINBLASTINE;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL SURVIVAL; CYCLOPHOSPHAMIDE; DACARBAZINE; FEMALE; HUMANS; LUNG NEOPLASMS; MELANOMA; MICE; MICE, SCID; SKIN NEOPLASMS; VINBLASTINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 68049148642     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3275     Document Type: Article

References (32)

1. Comis RL. DTIC (NSC-45388) in malignant melanoma: a perspective. Cancer Treat Rep 1976;60:165-176
2. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-166 (Pubitemid 30036349)
3. Ringborg U, Jungnelius U, Hansson J, Strander H. Dacarbazine-vindesine- cisplatin in disseminated malignant melanoma. Ap hase I-II trial. Am J Clin Oncol 1990;13:214-217 (Pubitemid 20247663)
4. Buzaid AC, Murren J. Chemotherapy for advanced malignant melanoma. Int J Clin Lab Res 1992;21:205-209
5. Chapman PB, Einhorn LH, Meyers ML, et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 1999;17:2745-2751 (Pubitemid 29415231)
6. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials. Lancet Oncol 2003;4:748-759 (Pubitemid 37527210)
7. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-436
8. KerbelRS,KlementG, PritchardKI,KamenB.Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 2002;13:12-15
9. Hermans IF, Chong TW, Palmowski MJ, et al. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res 2003;63:8408-8413
10. Spieth K, Kaufmann R, Gille J. Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: a pilot study. Cancer Chemother Pharmacol 2003;52:377-382 (Pubitemid 37363610)
11. Jia LJ, Wei DP, Sun QM, et al. Tumor-targeting Salmonella typhimurium improves cyclophosphamide chemotherapy at maximum tolerated dose and low-dose metronomic regimens in a murine melanoma model. Int J Cancer 2007; 121:666-674
12. Reichle A, Bross K, Vogt T, et al. Pioglitazone and rofecoxib combined with angiostatically scheduled trofosfamide in the treatment of faradvanced melanoma and soft tissue sarcoma. Cancer 2004;101:2247-2256 (Pubitemid 39458680)
13. Munoz R, Man S, Shaked Y, et al. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res 2006;66:3386-3391
14. Emmenegger U, Morton GC, Francia G, et al. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. CancerRes 2006;66:1664-1674 (Pubitemid 43259951)
15. Pietras K, Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemoswitch" regimen is antiangiogenic, producing objective responses and survival benefit in amouse model of cancer. J Clin Oncol 2005;23:939-952
16. Cruz-Munoz W, Man S, Xu P, Kerbel RS. Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. Cancer Res 2008;68:4500-4505
17. Lev DC, Ruiz M, Mills L, et al. Dacarbazine causes transcriptional up-regulation of interleukin 8 and vascular endothelial growth factor in melanoma cells: a possible escape mechanism from chemotherapy. Mol Cancer Ther 2003;2:753-763
18. Klement G, Baruchel S, Rak J, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000;105:R15-24. (Pubitemid 30217701)
19. Lacroix M. MDA-MB-435 cells are from melanoma, not from breast cancer. Cancer Chemother Pharmacol 2008;63:567.
20. Rae JM, Creighton CJ, Meck JM, et al. MDAMB- 435 cells are derived from M14 melanoma cells-a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat 2007;104:13-19
21. Christgen M, Lehmann U. MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther 2007;6:1355-1357 (Pubitemid 351590342)
22. Rae JM, Ramus SJ, WalthamM, et al. Common origins of MDA-MB-435 cells fromvarious sources with those shown to have melanoma properties. Clin Exp Metastasis 2004;21:543-552
23. Ellison G, Klinowska T, Westwood RF, et al. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 2002;55: 294-299 (Pubitemid 35193254)
24. Khan MA, Andrews S, Ismail-Khan R, et al. Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control 2006;13:211-217 (Pubitemid 44469742)
25. Kerbel RS. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived -but they can be improved. Cancer Biol Ther 2003;2:S134-9.
26. Gogas HJ, Kirkwood JM, Sondak VK. Chemotherapy for metastatic melanoma: time for a change?. Cancer 2007;109:455-464
27. Bibby MC. Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 2004;40: 852-857 (Pubitemid 38519764)
28. Man S, Munoz R, Kerbel RS. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing. Cancer Metastasis Rev 2007;26:737-747 (Pubitemid 350115117)
29. Dellapasqua S, Bertolini F, Bagnardi V, et al. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J Clin Oncol 2008;26:4899-4905
30. Quirbt I, Verma S, Petrella T, et al. Temozolomide for the treatment of metastatic melanoma. Curr Oncol 2007;14:27-33.
31. Lawson DH. Choices in adjuvant therapy of melanoma. Cancer Control 2005;12:236-241
32. Ascierto PA, Kirkwood JM. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008;6:62.